Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

Soledad Henriquez (1) , Jérémie Zerbit (1) , Timothée Bruel (2, 3) , Amani Ouedrani (4, 5) , Delphine Planas (2, 3) , Paul Deschamps (1) , Isabelle Staropoli (2) , Jérôme Hadjadj (1) , Bruno Varet (4) , Natalia Ermak (1) , Didier Bouscary (1, 6) , Lise Willems (1) , Guillemette Fouquet (1) , Justine Decroocq (1) , Patricia Franchi (1) , Benedicte Deau-Fischer (1) , Benjamin Terrier (1, 7) , Jérôme Tamburini (1, 8) , Lucienne Chatenoud (4, 5, 9) , Olivier Schwartz (2, 3) , Marguerite Vignon (1)

1 Hôpital Cochin [AP-HP]
2 CNRS-UMR3569 - Virus et Immunité - Virus and immunity
3 VRI - Vaccine Research Institute
4 CHU Necker - Enfants Malades [AP-HP]
5 INEM - UM 111 (UMR 8253 / U1151) - Institut Necker Enfants-Malades
6 IC UM3 (UMR 8104 / U1016) - Institut Cochin
7 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
8 UNIGE - Université de Genève = University of Geneva
9 UPD5 - Université Paris Descartes - Paris 5

Domains: Life Sciences [q-bio]; Microbiology and Parasitology; Virology

Soledad Henriquez, Jérémie Zerbit, Timothée Bruel, Amani Ouedrani, Delphine Planas, et al.. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma. Blood, 2022, 139 (6), pp.942-946. ⟨10.1182/blood.2021013714⟩. ⟨pasteur-03696807⟩